Report Overview:
The Nano-based Drug Delivery System refers to the use of nanoscale materials for the targeted delivery and controlled release of therapeutic agents. These nanosystems include nanoparticles, liposomes, dendrimers, micelles, and nanotubes that are engineered to improve drug solubility, stability, bioavailability, and efficacy while minimizing side effects. This advanced technology enables drugs to bypass biological barriers, reach specific sites in the body, and release their payloads in a controlled manner. Nanocarriers can be designed to respond to specific stimuli such as pH, temperature, or enzymatic activity, enhancing the precision of treatment. The system is pivotal in addressing challenges faced by conventional drug delivery mechanisms, especially for cancer, cardiovascular diseases, infectious diseases, and neurological disorders.
Market Value:
Global Nano-based Drug Delivery System market was valued at USD 4,365 million in 2024 and is projected to reach USD 5,239 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 2.7% during the forecast period.
CAGR of 2.7%
(2024 – 2032)
By Types:
• Less than 50nm
• 50-150nm
• 150-300nm
• Other
By Applications:
Hydrophilic Drugs
Hydrophobic Drugs
Key players include:
• Amgen
• Teva
• Roche
• UCB (Union Chimique Belge)
• Celgene
• Merck
• Gilead Sciences
• Sanofi
• Pfizer
